This ruling closes a minor product liability case with no financial impact on AbbVie. No market reaction expected. Monitor for any Illinois Supreme Court appeal petition, though unlikely given the record.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $209.41entry
- T+1 · 6mo ago +2.08%α +2.73% · $213.76
- T+5 · 6mo ago +1.77%α +0.15% · $213.12
- T+20 · 5mo ago +6.24%α +4.66% · $222.47
- T+60 · 3mo ago +18.79%α +13.94% · $248.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Illinois Appellate Court affirmed summary judgment for AbbVie in a product liability case over its XEN gel stent. The plaintiff failed to provide expert testimony that a manufacturing defect caused his injuries, ending the litigation in AbbVie's favor.
Court Ruling Details
Key Facts
- Appellate court affirmed summary judgment for AbbVie in strict product liability action.
- Plaintiff alleged XEN gel stent had chemical residue causing eye injuries but lacked expert causation evidence.
- Non-precedential order under Illinois Supreme Court Rule 23(e)(1).
- No damages awarded, no injunction, no class action.
Financial Impact
No damages awarded; litigation costs immaterial relative to $371.7B market cap.
Risk Factors
- Potential plaintiff appeal to Illinois Supreme Court is low probability and would not change outcome without expert evidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3c4wl60q-ABBV |
Track record
22 reports on ABBV
7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers